Skip to content
10-Q

Quarterly Report

BridgeBio Pharma, Inc. BBIO

0001743881-26-000019

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 195.86M sh
Shares Diluted Q1 2026 · Mar 31, 2026 194.79M sh
Shares Diluted Q1 2026 · Mar 31, 2025 190.15M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $82.5M
Stock Repurchased Q1 2026 · Mar 31, 2025 $48.28M
Capex Q1 2026 · Mar 31, 2026 $69K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$197.28M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$199.24M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $879.89M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $570.12M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $540.6M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$2.28B
Stockholders Equity Q1 2026 · Dec 31, 2025 −$2.09B
Current Liabilities Q1 2026 · Mar 31, 2026 $816.37M
Current Liabilities Q1 2026 · Dec 31, 2025 $287.97M
Total Liabilities Q1 2026 · Mar 31, 2026 $3.64B
Total Liabilities Q1 2026 · Dec 31, 2025 $3.01B
Current Assets Q1 2026 · Mar 31, 2026 $1.24B
Current Assets Q1 2026 · Dec 31, 2025 $797.75M
Total Assets Q1 2026 · Mar 31, 2026 $1.37B
Total Assets Q1 2026 · Dec 31, 2025 $936.03M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.84
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.88
Eps Basic Q1 2026 · Mar 31, 2026 −$0.84
Eps Basic Q1 2026 · Mar 31, 2025 −$0.88
Sga Expense Q1 2026 · Mar 31, 2026 $163.9M
Sga Expense Q1 2026 · Mar 31, 2025 $106.37M
Rd Expense Q1 2026 · Mar 31, 2026 $126.64M
Rd Expense Q1 2026 · Mar 31, 2025 $111.43M
Operating Income Q1 2026 · Mar 31, 2026 −$105.96M
Operating Income Q1 2026 · Mar 31, 2025 −$104.37M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $9.94M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $2.64M
Revenue Q1 2026 · Mar 31, 2026 $194.52M
Revenue Q1 2026 · Mar 31, 2025 $116.63M